Drug Trial Radar · NCT04887831
Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab
Last checked: Nov 20, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
92
Actual
Start
Jun 4, 2021
Primary completion
Apr 7, 2023
Study completion Mar 1, 2024
Sponsor
- Lead sponsor
- G1 Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2, multicenter, randomized, open-label study evaluating the safety and efficacy of trilaciclib administered with platinum-based chemotherapy followed by trilaciclib administered with avelumab maintenance therapy compared with platinum-based chemotherapy followed by avelumab maintenance therapy in participants receiving first-line treatment for advanced/metastatic urothelial carcinoma.
Conditions
- Urothelial Carcinoma
- Bladder Cancer
- Myelosuppression Adult
- Chemotherapy-induced Neutropenia
- Metastatic Bladder Cancer
Interventions
TrilaciclibDrug
Trilaciclib administered IV prior to chemotherapy and avelumab maintenance therapy on each day chemotherapy and avelumab maintenance therapy is administered.
GemcitabineDrug
Gemcitabine administered IV on Day 1 and Day 8 of each 21-day cycle
CisplatinDrug
Cisplatin administered IV on Day 1 of each 21-day cycle
CarboplatinDrug
Carboplatin administered IV on Day 1 of each 21-day cycle
AvelumabDrug
Avelumab administered IV on Day 1 of each 14-day maintenance cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Progression-Free Survival (PFS) During Overall StudyTime frame: From date of randomization until date of documented radiologic disease progression per RECIST v1.1 or death due to any cause, whichever comes first. Approximately 96 weeks
Locations
34 sites in 5 countries. Site status is shown where the registry gives one.
Valkyrie Clinical Trial
Los Angeles, California
The Oncology Institute of Hope and Innovation
Whittier, California
Rocky Mountain Cancer Centers
Littleton, Colorado
Florida Cancer Specialists - South
Fort Myers, Florida
Woodlands Medical Specialists
Pensacola, Florida
Florida Cancer Specialists - North
St. Petersburg, Florida
Beacon Cancer Center PLLC
Coeur d'Alene, Idaho
The Harry and Jeanette Weinberg Cancer Institute
Baltimore, Maryland
New York Oncology Hematology, P.C.
Albany, New York
Montefiore Medical Center
The Bronx, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Northwest Cancer Specialists, P.C.
Tigard, Oregon
Tennessee Oncology, PLLC
Nashville, Tennessee
Centre Léon Bérard - Département d'oncologie médicale
Lyon, France
Hôpital Européen Georges Pompidou - Service d'Oncologie Médicale
Paris, France
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, France
Hopitaux Universitaires de Strasbourg - Service Oncologie et Hématologie
Strasbourg, Bas-Rhin, France
Institut Bergonié - Oncologie Médicale et Pédiatrique
Bordeaux, Gironde, France
National Center of Urology Named after Laur Managadze
Tbilisi, Georgia
LTD "Multiprofile Clinic Consilium Medulla"
Tbilisi, Georgia
High Technology Hospital MedCenter LTD
Batumi, Adjara, Georgia
Országos Onkológiai Intézet
Budapest, Hungary
Uzsoki Utcai Kórház
Budapest, Hungary
Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz - Rendeloint
Szolnok, Jász-Nagykun-Szolnok, Hungary
Hospital Universitario Vall d´Hebron
Barcelona, Spain
Hospital Clinic de Barcelona - Servicio de Oncología Médica
Barcelona, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
H.U. V. de las Nieves
Granada, Spain
Hospital Universitario Lucus Augusti
Lugo, Spain
Fundación Instituto Valenciano de Oncología
Valencia, Spain
Hospital Politecnic Universitari La Fe
Valencia, Spain
Institut Català d'Oncologia-Hospital Universitari Germans Trias i Pujol
Badalona, Barcelona, Spain
ALTHAIA, Xarxa Assistencial Universitiria de Manresa
Manresa, Barcelona, Spain
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.